文献速递流行病学与生物统计临床试验与 GCP

随机临床试验中观察者偏倚的实证证据:对同时设有盲法与非盲法结局评估者的试验的更新与扩展分析

Empirical evidence of observer bias in randomized clinical trials: updated and expanded analysis of trials with both blinded and non-blinded outcome assessors.
PubMed 文献 · J Clin Epidemiol · 2025-04-19

该Meta流行病学研究纳入66项随机试验(9451例患者),比较同一试验内盲法与无盲法结局评估者所得效应估计。作者结论强烈支持对主观结局采用盲法评估。

要点

  • 非盲结局评估者平均夸大以比值比表示的效应29%(8%-45%)。
  • 非药物试验ROR 0.62(0.46-0.84)与产业资助试验ROR 0.57(0.37-0.88)中影响更大。

核心结论

  • 随机试验中非盲评估者对主观二分类和测量量表结局的效应估计存在相当程度的偏倚。
  • 非盲评估者平均将比值比表示的效应夸大29%(8%-45%)。
  • 作者结论强烈支持对主观结局的评估者采用盲法。

研究设计与样本

  • Meta流行病学研究,纳入分配至有或无盲法结局评估子试验、或对同一结局同时有盲法与无盲法评估的随机试验。
  • 从既往Meta流行病学研究及2013年至2024年六个数据库检索识别试验。
  • 共纳入18个临床专科的66项试验(9451例患者),其中43项试验(7055例患者)纳入汇总分析。

主要发现

  • 43项试验中30项评估高度主观结局。
  • Meta回归显示ROR与结局主观性评分(P=0.53)、脆弱性评分(P=0.91)和参与度评分(P=0.99)无统计学显著关联。
  • 纳入23项试验(2396例随机化患者)插补数据的敏感性分析未重要改变观察到的效应。

关键数值与推荐

  • ROR<1表示非盲评估者给出的效应估计更有利。
  • 采用随机效应Meta分析汇总ROR,并进行Meta回归、亚组和敏感性分析。

临床怎么用

  • 作者结论强烈支持对主观结局的评估者采用盲法。
  • 作者指出当随机试验中患者评估需要判断时,评估者非盲可能产生相当程度的偏倚,为确保结果更可靠,随机临床试验应尽可能对评估者设盲。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the impact of lack of blinding of outcome assessors on estimated treatment effects of randomized clinical trials. STUDY DESIGN AND SETTING: Meta-epidemiological study. We included randomized trials with binary or measurement scale outcomes that (1) allocated patients to subtrials with and without blinded outcome assessment, or (2) had both blinded and non-blinded assessments of the same outcome. We identified trials from previous meta-epidemiological studies and searched six databases from 2013 to 2024. We calculated a ratio of odds ratios (ROR) for each trial. A ROR < 1 indicated a more favorable effect estimate by the non-blinded assessor. We pooled RORs using random effects meta-analysis and conducted meta-regression, subgroup, and sensitivity analyses. RESULTS: We included 66 trials (9451 patients) across 18 clinical specialties. The pooled RORs in 43 trials (7055 patients) was 0.71 (0.55-0.92). Thirty of the 43 trials assessed highly subjective outcomes. Meta-regression showed no statistically significant association between ROR and scores for outcome subjectivity (P = .53), vulnerability (P = .91), and involvement (P = .99). Heterogeneity was partly explained by a larger impact in non-drug trials, ROR 0.62 (0.46-0.84), and industry-funded trials, ROR 0.57 (0.37-0.88). Sensitivity analyses, including imputed data for 23 trials (2396 patients randomized), did not modify the observed impact importantly. CONCLUSION: We provide empirical evidence of considerable bias in effect estimates of randomized trials with non-blinded assessors of subjective binary and measurement scale outcomes. Non-blinded assessors exaggerated effect estimates, expressed as odds ratios, by 29% (8%-45%) on average. This strongly supports blinding outcome assessors of subjective outcomes. PLAIN LANGUAGE SUMMARY: In a randomized clinical trial, the person evaluating the results (assessor) may be either unaware of the intervention received by participants (blinded assessor) or aware of it (non-blinded assessor). Knowing which treatment a patient received can influence the assessor's evaluation of the effect; for example, if an assessor has high expectations for a new experimental intervention, they may rate a patient's improvement more favorably in the group that received the intervention compared to the group that did not. We call this observer bias. In this study, we compared the results obtained from blinded assessors to those from non-blinded assessors within the same trials to estimate the impact of observer bias in randomized trials. We found that non-blinded assessors exaggerated the experimental intervention effect by approximately 29%, on average, compared to blinded assessors. Our results indicate that when an evaluation of a patient in a randomized trial requires judgment, there is potential for substantial bias if assessors are not blinded. To ensure more reliable results, randomized clinical trials should blind assessors whenever possible.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Salazar J, Moustgaard H, Bracchiglione J, et al. Empirical evidence of observer bias in randomized clinical trials: updated and expanded analysis of trials with both blinded and non-blinded outcome assessors. J Clin Epidemiol. 2025. PMID: 40258524. doi:10.1016/j.jclinepi.2025.111787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。